GJC1: A Drug Target / Disease Biomarker (G10052)

Target Name: GJC1

NCBI ID: G10052

GJC1

GJC1: A Drug Target / Disease Biomarker

GJC1, also known as G protein-coupled receptor 1, is a protein that is expressed in many different tissues throughout the body. It is a member of the G protein-coupled receptor family, which is a large family of transmembrane proteins that play an important role in cellular signaling. GJC1 is one of the most well-studied members of this family, and a number of potential drug targets and biomarkers have been identified based on its structure and function.

GJC1 is a transmembrane protein that is composed of an extracellular region, a transmembrane region, and an intracellular region. The extracellular region consists of a N-terminus that is involved in cell adhesion, and a C-terminus that is involved in signaling interactions with other proteins. The transmembrane region consists of a protein that is similar in structure to the extracellular domain of other G protein-coupled receptors, and the intracellular region consists of a protein that is similar in structure to the intracellular domain of other G protein-coupled receptors.

GJC1 is involved in a wide range of physiological processes in the body, including sensory perception, neurotransmitter signaling, and cell signaling. It is thought to play a role in the regulation of pain, anxiety, and depression, as well as in the regulation of appetite and body weight.

One of the most promising aspects of GJC1 is its potential as a drug target. Several studies have identified potential drug candidates that are thought to interact with GJC1, including small molecules, peptides, and proteins. Many of these candidates come from a variety of different chemical families, including sensory neurotransmitters, neurotransmitter receptor antagonists, and protein kinases.

One of the most promising candidates is a small molecule called GJC1 antagonist-1 (GJC1-A), which is a compound that is thought to inhibit the activity of GJC1. GJC1-A is currently being tested as a potential drug for the treatment of anxiety and depression.

Another promising candidate is a peptide called P2R, which is a short peptide that is thought to interact with GJC1. P2R is currently being tested as a potential drug for the treatment of anxiety and depression.

In addition to these candidates, GJC1 is also thought to be a potential biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and psychiatric disorders. This is because its expression is often reduced in these diseases, and changes in GJC1 expression have been observed that may be associated with the development and progression of these diseases.

Overall, GJC1 is a well-studied protein that is involved in a wide range of physiological processes in the body. Its structure and function have led to the identification of several potential drug targets and biomarkers, making it an attractive target for research and development of new therapies.

Protein Name: Gap Junction Protein Gamma 1

Functions: One gap junction consists of a cluster of closely packed pairs of transmembrane channels, the connexons, through which materials of low MW diffuse from one cell to a neighboring cell

The "GJC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GJC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets